iparomlimab + tuvonralimab

**Iparomlimab + tuvonralimab** is Qilu Pharmaceutical's fixed-proportion PD-1/CTLA-4 checkpoint-inhibitor antibody combination, developed using the MabPair platform and also known as QL1706. It contains the anti-PD-1 IgG4 monoclonal antibody iparomlimab and the anti-CTLA-4 IgG1 monoclonal antibody tuvonralimab in a fixed 2:1 ratio. Dual checkpoint blockade enhances antitumor T-cell activity by releasing PD-1- and CTLA-4-mediated inhibitory signaling; the CTLA-4 component was engineered for a relatively shorter exposure intended to balance efficacy with immune-related toxicity. In September 2024, the product received conditional marketing approval in China for recurrent or metastatic cervical cancer that progressed after platinum-based chemotherapy. It is also in clinical development across multiple solid tumors. ([qilu-pharma.com](https://www.qilu-pharma.com/news_details/419.html))

Brand names

齐倍安

Other names

iparomlimab and tuvonralimabiparomlimab + tuvonralimabiparomlimab/tuvonralimab艾帕洛利托沃瑞利单抗艾托组合抗体